Respien Pty Ltd is an Australian clinical stage drug development company targeting the top 5 cause of death global - chronic lung conditions (like chronic bronchitis & emphysema, collectively called COPD). With Covid dramatically increasing COPD, the company believes it can disrupt the multi-billion dollar COPD pharma care industry with its three clinically tested, better performing products.
Pathify Holdings Inc. is a rapidly growing SaaS student portal provider used by universities, colleges and higher education institutions. The Company is focussed on the US higher education market, with a target market of over 6,000 institutions.
Grow Finance Limited is an award winning non-bank financier for small and medium sized Australian businesses (SME). Grow has advanced over $1bn in loans since inception across asset finance, trade finance, invoice finance and insurance premium funding. These groups represent a A$422bn target loan segment.
The Truwell Group Ltd Offer has closed. Truwell Group Pty Ltd has been developed by leading educators, Dr Tim Hawkes OAM and Adam Webber, to help students, teachers and parents manage mental health and wellbeing in an increasingly stressful world.
The Neopharma Technologies Ltd Offer has closed.
Neopharma participates in the US$6 billion global drugs-of-abuse testing market with its patented, trademarked and tamper-proof drugs-of-abuse testing solution - TamperLoks DataVault.
Spacetalk Ltd (ASX:SPA) is Australia’s leading manufacturer of smartwatches for children and seniors paired with software which enables guardians to care for them. Total addressable market is A$17bn in countries where the company is present (including ANZ, UK and US).
Exclusive access to private investments which are only available to Capital Club members. Now's the time to join.
Early notifications on time restricted offers, access to early stage companies and opportunities for discounted placements.
Once you've become a qualified investor, ALL Capital Club opportunities are available to you.
OnMarket 2021 IPO Report available here. ASX IPOs in 2021 returned an average of 15.2% for 2021, outperforming the ASX200 by 2.1%
*Based on both open and closed positions of the 191 listed offers as at 1 August 2022.
Performance figures are calculated using a simple average method.